IGF1 and neoplasm: It also curtails insulin-driven tumorigenesis via the IGF-1 signaling pathway and boosts anti-tumor T-cell activity while suppressing immunosuppressive cells, potentially enhancing immunotherapies [19, 87] (Fig. 3).